NeuroVive Pharmaceutical publishes 2015 annual report
April 07, 2016 02:30 ET
|
NeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical AB (publ) today announced that the English version of
the annual report for 2015 is now available on the company’s website
www.neurovive.com. The annual report can also be...
NeuroVive Pharmaceutical publicerar årsredovisningen för 2015
April 07, 2016 02:30 ET
|
NeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical AB (publ) meddelar idag att årsredovisningen för 2015
finns tillgänglig på bolagets hemsida www.neurovive.com samt kan läsas via
länken nedan.
Om NeuroVive
NeuroVive...
NeuroVive Pharmaceutical AB (publ): report from EGM
March 31, 2016 07:00 ET
|
NeuroVive Pharmaceutical AB
Today, 31 March 2016, an extraordinary general meeting was held in NeuroVive
Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the
resolutions follows. All resolutions were passed...
NeuroVive Pharmaceutical AB (publ): kommuniké från extra bolagsstämma
March 31, 2016 07:00 ET
|
NeuroVive Pharmaceutical AB
Idag, den 31 mars 2016, hölls en extra bolagsstämma i NeuroVive Pharmaceutical
AB (publ) (”NeuroVive” eller ”Bolaget”). Nedan följer en sammanfattning av de
beslut som fattades. Samtliga beslut...
Kallelse till årsstämma i NeuroVive Pharmaceutical AB (publ)
March 29, 2016 02:30 ET
|
NeuroVive Pharmaceutical AB
Aktieägarna i NeuroVive Pharmaceutical AB (publ), 556595-6538, kallas härmed
till årsstämma torsdagen den 28 april 2016 kl. 16.00 på Medicon Village,
Scheelevägen 2, i Lund, med insläpp för...
Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)
March 29, 2016 02:30 ET
|
NeuroVive Pharmaceutical AB
The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity
number 556595-6538, are hereby convened to the Annual General Meeting, held at 4
p.m. on Thursday, 28 April 2016 at Medicon...
NeuroVive meddelar att CiPRICS-studien passerar säkerhetsutvärdering efter 100 inkluderade patienter
March 14, 2016 03:30 ET
|
NeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical AB (publ), läkemedelsbolaget inom mitokondriell
medicin, meddelar att den oberoende kommitté som utvärderar säkerheten i den
pågående fas II-studien med bolagets produkt...
NeuroVive announces the CiPRICS study enrols 100 patients and reports favourable safety evaluation
March 14, 2016 03:30 ET
|
NeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine,
announces that the independent safety committee has once again endorsed the
continuation of the ongoing Phase II CiPRICS...
Kallelse till extra bolagsstämma i NeuroVive Pharmaceutical AB (publ)
February 29, 2016 02:40 ET
|
NeuroVive Pharmaceutical AB
Aktieägarna i NeuroVive Pharmaceutical AB (publ), org.nr 556595-6538 (”Bolaget”)
kallas härmed till extra bolagsstämma torsdagen den 31 mars 2016 kl. 10.00 på
Grand Hotel Lund, Bantorget 1 i Lund, med...
Notice of extraordinary general meeting in NeuroVive Pharmaceutical AB (publ)
February 29, 2016 02:40 ET
|
NeuroVive Pharmaceutical AB
The shareholders in NeuroVive Pharmaceutical AB (publ) reg. no. 556595-6538
(the “Company”) are hereby convened to the extraordinary general meeting, held
at 10.00 a.m. on Thursday, 31 March 2016 at...